Last reviewed · How we verify
GB1211
At a glance
| Generic name | GB1211 |
|---|---|
| Sponsor | Galecto Biotech AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma (PHASE1)
- GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma (PHASE2)
- A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). (PHASE1, PHASE2)
- A Study to Compare Pharmacokinetics of GB1211 (PHASE1)
- A Single and Repeat Dose Trial in Participants With Hepatic Impairment (PHASE1, PHASE2)
- A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects (PHASE1)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GB1211 CI brief — competitive landscape report
- GB1211 updates RSS · CI watch RSS
- Galecto Biotech AB portfolio CI